OMCL vs. SLNO, AKRO, KNSA, IRWD, WRBY, DCPH, PCRX, TARS, BKD, and ABCL
Should you be buying Omnicell stock or one of its competitors? The main competitors of Omnicell include Soleno Therapeutics (SLNO), Akero Therapeutics (AKRO), Kiniksa Pharmaceuticals (KNSA), Ironwood Pharmaceuticals (IRWD), Warby Parker (WRBY), Deciphera Pharmaceuticals (DCPH), Pacira BioSciences (PCRX), Tarsus Pharmaceuticals (TARS), Brookdale Senior Living (BKD), and AbCellera Biologics (ABCL). These companies are all part of the "medical" sector.
Soleno Therapeutics (NASDAQ:SLNO) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk.
Soleno Therapeutics presently has a consensus target price of $55.60, indicating a potential upside of 45.47%. Omnicell has a consensus target price of $42.20, indicating a potential upside of 57.17%. Given Soleno Therapeutics' higher probable upside, analysts plainly believe Omnicell is more favorable than Soleno Therapeutics.
Soleno Therapeutics has a beta of -1.56, suggesting that its stock price is 256% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.
In the previous week, Omnicell had 5 more articles in the media than Soleno Therapeutics. MarketBeat recorded 7 mentions for Omnicell and 2 mentions for Soleno Therapeutics. Omnicell's average media sentiment score of 0.30 beat Soleno Therapeutics' score of 0.07 indicating that Soleno Therapeutics is being referred to more favorably in the media.
Omnicell has higher revenue and earnings than Soleno Therapeutics. Omnicell is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.
97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 23.7% of Soleno Therapeutics shares are owned by insiders. Comparatively, 2.6% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Omnicell received 193 more outperform votes than Soleno Therapeutics when rated by MarketBeat users. However, 71.22% of users gave Soleno Therapeutics an outperform vote while only 67.77% of users gave Omnicell an outperform vote.
Soleno Therapeutics has a net margin of 0.00% compared to Soleno Therapeutics' net margin of -1.78%. Soleno Therapeutics' return on equity of 3.43% beat Omnicell's return on equity.
Summary
Omnicell beats Soleno Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Omnicell News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Omnicell Competitors List
Related Companies and Tools
